Chronic Plaque Psoriasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Chronic Plaque Psoriasis Market Outlook

Thelansis’s “Chronic Plaque Psoriasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Plaque Psoriasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Plaque Psoriasis Overview

Chronic plaque psoriasis, also known as psoriasis vulgaris, represents a persistent inflammatory dermatological condition characterized by well-defined, erythematous, and scaly plaques predominantly affecting the body's and scalp's extensor surfaces. These lesions may intermittently elicit pruritus or a stinging sensation and can exhibit bleeding upon trauma. Dystrophic nail alterations, including nail pitting, are observed in over a third of individuals with chronic plaque psoriasis, while psoriatic arthropathy manifests in 1% to over 10% of cases. The disease course of chronic plaque psoriasis is marked by periods of exacerbation and remission, exhibiting substantial inter-individual variability in severity and progression. Additional subtypes of psoriasis include guttate, inverse, pustular, and erythrodermic presentations. While approximately one-third of individuals affected by psoriasis have a familial predisposition to the disease, external factors such as physical trauma, acute infections, and certain medications (e.g., lithium and beta-blockers) are implicated in triggering disease onset. Observational evidence suggests associations between psoriasis and stressful life events, cigarette smoking, and, to a lesser extent, alcohol consumption. Additionally, correlations have been reported between psoriasis and factors such as body mass index (BMI) and dietary patterns low in fruits and vegetables. Diagnosis of psoriasis relies primarily on the clinical presentation of cutaneous lesions. However, a biopsy may be warranted to differentiate psoriasis from similar-appearing conditions such as lichen simplex chronicus, nummular eczema, seborrheic dermatitis, and tinea corporis. While chronic plaque psoriasis generally does not impact life expectancy, it can be complicated by various comorbidities, including malignancies, arthritis, and emotional distress stemming from its cosmetic repercussions. Concomitant psychological manifestations such as depression, anxiety, sexual dysfunction, low self-esteem, and suicidal ideation may co-occur with psoriasis, even in cases of milder disease severity. Topical therapies form the cornerstone of psoriasis management and encompass a range of agents, including steroids, vitamin D derivatives, retinoids, immunosuppressants, anthralin, coal tar ointment, and various other modalities.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: